Accéder au contenu
Merck

POLYRETINA restores light responses in vivo in blind Göttingen minipigs.

Nature communications (2022-06-28)
Paola Vagni, Marta Jole Ildelfonsa Airaghi Leccardi, Charles-Henri Vila, Elodie Geneviève Zollinger, Golnaz Sherafatipour, Thomas J Wolfensberger, Diego Ghezzi
RÉSUMÉ

Retinal prostheses hold the potential for artificial vision in blind people affected by incurable diseases of the outer retinal layer. Available technologies provide only a small field of view: a significant limitation for totally blind people. To overcome this problem, we recently proposed a large and high-density photovoltaic epiretinal device, known as POLYRETINA. Here, we report the in vivo assessment of POLYRETINA. First, we characterise a model of chemically-induced blindness in Göttingen minipigs. Then, we develop and test a minimally invasive injection procedure to insert the large epiretinal implant into the eye. Last, we show that POLYRETINA restores light-evoked cortical responses in blind animals at safe irradiance levels. These results indicate that POLYRETINA holds the potential for artificial vision in totally blind patients affected by retinitis pigmentosa.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-opsine (bleue), Chemicon®, from rabbit
Sigma-Aldrich
Anti-Rabbit IgG (H+L), CF 488A antibody produced in goat, ~2 mg/mL, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-Na+/K+ ATPase (α3 Subunit) antibody produced in mouse, 1 mg/mL, clone XVIF9-G10, ascites fluid